SUTRO BIOPHARMA INC
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
STRO$10.17-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In- · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2023 | 61,009,829 | $61 | $708,975 | $21 | $(559,408) | $149,649 |
| Exercise of common stock options | 23,748 | — | 117 | — | — | 117 |
| Issuance of common stock under Employee Stock Purchase Plan | 284,362 | — | 911 | — | — | 911 |
| Vesting of restricted stock units | 1,215,729 | 1 | (1) | — | — | — |
| Stock transaction associated with taxes withheld on restricted stock units | (77,122) | — | (374) | — | — | (374) |
| Stock-based compensation expense | — | — | 6,068 | — | — | 6,068 |
| Net unrealized income on available-for-sale securities | — | — | — | (134) | — | (134) |
| Net loss | — | — | — | — | (58,213) | (58,213) |
| Balances at March 31, 2024 | 62,456,546 | $62 | $715,696 | $(113) | $(617,621) | $98,024 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In- · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | (Loss) | Deficit | Equity | |
| Balances at December 31, 2022 | 57,499,541 | $58 | $670,223 | $(618) | $(452,615) | $217,048 |
| Exercise of common stock options | 53,060 | — | 314 | — | — | 314 |
| Issuance of common stock under Employee Stock Purchase Plan | 239,060 | — | 1,097 | — | — | 1,097 |
| Vesting of restricted stock units | 801,769 | — | — | — | — | — |
| Stock transaction associated with taxes withheld on restricted stock units | (73,003) | — | (451) | — | — | (451) |
| Stock-based compensation expense | — | — | 6,021 | — | — | 6,021 |
| Issuance of common stock in connection with At-The-Market sale, net of issuance costs of $308 | 1,641,374 | 2 | 10,921 | — | — | 10,923 |
| Net unrealized income on available-for- sale securities | — | — | — | 511 | — | 511 |
| Net loss | — | — | — | — | (50,050) | (50,050) |
| Balances at March 31, 2023 | 60,161,801 | $60 | $688,125 | $(107) | $(502,665) | $185,413 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.